NCT04951050View on ClinicalTrials.gov

TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment

NAActive, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

August 26, 2023

Study Completion Date

December 31, 2027

Conditions
Coronary Artery DiseaseCoronary Stenosis
Interventions
DEVICE

Rapamycin target eluting stent

Rapamycin target eluting stent

Trial Locations (1)

514000

Meizhou Peple's Hospital, Meizhou

All Listed Sponsors
lead

Shanghai MicroPort Medical (Group) Co., Ltd.

INDUSTRY

NCT04951050 - TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment | Biotech Hunter | Biotech Hunter